In particular, CD19-reactive CAR T cells have yielded impressive response rates against hematologic malignancies such as B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B cell lymphoma (DLBCL)1. Here, CD19 is linked to diffuse large B-cell lymphoma.